A History
of Impact

From the beginning, our goal has been to take on the world’s toughest health challenges. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community, and uncompromising integrity at the heart of everything we do. But we haven’t come this far to only come this far.

Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.

Our commitment to equality

AbbVie is committed to making a positive impact in the fight for racial justice. To address the ongoing issues in our criminal justice system, we’ve donated $5 million to the NAACP Legal Defense and Education Fund and the Equal Justice Initiative. Over the next five years, we are partnering with nonprofits in our communities to donate an additional $50 million.

Our response to the COVID-19 pandemic

AbbVie is committed to addressing the COVID-19 public health crisis. We’ve partnered with health authorities and institutions to accelerate R&D into treatment and prevention. Additionally, AbbVie donated $35 million to underserved communities and healthcare systems.

From collaborating in clinical research to providing equipment and supplies, we’ll continue to keep the health and safety of communities and our employees at the forefront of our efforts.


Our rheumatoid arthritis treatment RINVOQ received FDA approval

Discovered and developed in AbbVie’s labs, RINVOQ™ (upadacitinib) was granted FDA approval in the U.S. for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate, marking our second FDA approval of a targeted immunomodulator (TIM) therapy in 2019. This milestone has helped many people living with RA achieve clinical remission or low disease activity and continues our long-standing commitment to advancing the treatments available for people living with immune-mediated conditions.

AbbVie honored on CR Magazine’s annual 100 Best Corporate Citizens List

Corporate responsibility is a critical part of who we are as a company, which is why we were delighted to be ranked 17th on CR Magazine’s annual 100 Best Corporate Citizens List. This influential list recognizes outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies.

Our plaque psoriasis treatment SKYRIZI received global regulatory approvals

AbbVie’s SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, received both FDA and European Commission approvals for the treatment of severe plaque psoriasis, a chronic condition affecting 125 million people worldwide.


FDA accelerated approval for newly-diagnosed acute myeloid leukemia (AML) patients

AbbVie was granted accelerated approval for a treatment for newly-diagnosed AML in adults 75 years or older, or who have comorbidities that preclude intensive induction chemotherapy. AML is one of the most aggressive blood cancers, and this new approval marked a significant milestone for patients diagnosed with this disease.

AbbVie donated $100 million to Ronald McDonald House Charities

This contribution, the largest single donation in both AbbVie and Ronald McDonald House Charities history, provided essential support such as housing, meals and education for hospitalized children and their families across America.

AbbVie recognized as a FORTUNE 100 Best Company to Work For

In 2018, we were proud to be featured in the FORTUNE 100 Best Companies to Work For list for the first time. At AbbVie, culture has always been a strategic priority, and our employees are unified by a commitment to make a remarkable impact on patients’ lives.


MAVIRET™ / MAVYRET™ (glecaprevir/pibrentasvir) was approved in U.S., European Union and Japan

AbbVie Topped Barron’s 500

The company moved to 2nd on the list, up from 32 in 2016.


AbbVie led biotech industry in Dow Jones Sustainability World Index

For the third year in a row, AbbVie placed highly on the Dow Jones Sustainability World Index, which measures performance of the world’s largest companies based on long-term economic, environmental, and social criteria and business practices that create long-term shareholder value. In 2016, we had the highest industry score on 12 of 22 criteria.

Our treatment for uveitis was approved by the U.S. Food and Drug Administration

We received a new approval for our biologic treatment for non-infectious uveitis, an immune-mediated disease that can flare and impair vision.

We earned new approvals for IMBRUVICA® (ibrutinib) and VENCLEXTA™ / VENCLYXTO™ (Venetoclax)

By earning these approvals in the United States and European Union, we furthered our commitment to tackling the world's toughest diseases.


IMBRUVICA® (ibrutinib) awarded Prix Galien 2015 Best Pharmaceutical Agent

Considered to be the biomedical industry's highest accolade, the Prix Galien Award recognizes outstanding achievement in the development of new therapies. Worldwide, the Prix Galien Award is generally regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

AbbVie made Working Mother of the Year list for 3rd year in a row

Working Mother magazine recognized AbbVie among its “Working Mother 100 Best Companies” for the third consecutive year. This recognition is given for outstanding leadership in creating progressive programs, advancement of women, flexibility, childcare and paid parental leave for employees like Sandra.

We gained a new indication approval for the treatment of moderate to severe hidradenitis suppurativa

We received the first U.S. FDA approval for HS, a chronic inflammatory skin disease.

The U.S. FDA approved our Parkinson's disease treatment

The FDA approved our medicine for the treatment of motor fluctuations for people with advanced Parkinson's disease.


Our first AbbVie-created medicine was approved

The first medicine developed independently by AbbVie, VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets), was approved in the United States.

AbbVie medicines impact over 30 million patients around the world

With a new indication approval in the United States, we had collectively served over 30 million patients worldwide with our medicines.

AbbVie announced novel collaboration on aging with Calico

We joined forces with Calico, Alphabet’s life sciences research company, to tackle health issues that affect the world's aging population.


“The AbbVie Way” became a unified culture

Our new company needed its own culture, and we quickly got to work implementing changes that would drive performance and success through our business, our culture and our remarkable impact. Find out how we built “The AbbVie Way,” and what it means to truly live it.

AbbVie ranked 4th on Science magazine's list of top science employers

After less than a year of existence, AbbVie ranked 4th on Science magazine's annual list of Top Science Employers, as surveyed by more than 3,000 respondents.

We earned our first breakthrough therapy designation from the U.S. Food and Drug Administration

With 71 million people worldwide infected with hepatitis C (HCV), our ongoing commitment to those living with the virus means understanding their journey. That's why we were thrilled when the FDA gave us this designation, intended to expedite the development and review of drugs for serious or life-threatening conditions, for our investigational HCV regimen.

The first AbbVie-branded product was released into the world

The first batch of AbbVie-branded HUMIRA® (adalimumab) pens rolled off the production line. Within 24 hours, approximately 23,000 finished cartons – 46,000 pens – had been made for patients in the United States.

We’re on a mission

Learn more about our commitments to our patients, our communities and a strong financial future.
Learn more